Skip to main content

Table 1 Summary of the clinicopathologic features of T-cell lymphoproliferative disorder following autologous hematopoietic stem cell transplantation

From: T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein–Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma

  Age at onset of first neoplasm Histological diagnosis of first neoplasm Therapy before AutoHSCT Histological diagnosis of T-cell LPD Histological findings EBV (ISH or PCR) Areas of T-cell LPD Time of T-cell LPD onset after HSCT Outcome Reference
1 48 years HL (1) Doxorubicin-based chemotherapy
(2) High-dose cytosine arabinoside
(3) Conditioning regimen that included cyclophosphamide, etoposide, and ranimustine
T-cell PTLD (Lymph node) Lymphoid hyperplasia with mild sinus histiocytosis, as well as proliferation of epithelioid cells. Positive Mesenteric lymph nodes 2 years and
6 months
Fatal [12]
2 61 years AITL (1) Four cycles of CHOP
(2) High-dose etoposide
(3) Two cycles of CHOP
(4) Ranimustine, cyclophosphamide, etoposide, and carboplatin
T-LGL (Blood) Pronounced lymphocytosis of large-sized lymphoid cells with round to indented nuclei, coarse chromatin, and azurophilic cytoplasmic granules. Negative Bone marrow 1 month Survival [13]
3 62 years FL (1) Eight cycles of CHOP
(2) Two cycles of MINE
(3) Etoposide
(4) Ranimustine, carboplatin, etoposide, and cyclophosphamide
AITL (Lymph node) Diffuse infiltration of medium to large-sized lymphoid cells with predominant proliferation of small blood vessels. Positive Cervical and supraclavicular lymph nodes 4 months Resolved [14]
4 49 years AITL (1) Five cycles of CHOP
(2) Salvage chemotherapy: ESHAP
T-cell PTLD (Autopsy) Lymphoid cells in the bone marrow, portal area of the liver, lymph nodes and lungs.
The hypocellularity in the marrow with the proliferation of macrophages and marked hemophagocytosis.
Macrophages in the marrow, liver, lymph nodes, and lungs.
Positive Bone marrow, liver, lungs, lymph nodes 3 months Fatal [15]
5 47 years DLBCL High-dose radiotherapy and chemotherapy Enteropathy type T-cell lymphoma (Jejunum) An atypical destructive lymphoid infiltration with intraepithelial lymphocytes in the superficial mucosa and in the glands. Negative Jejunum, duodenum,
mesenteric lymph nodes
6 years and
3 months
Resolved [16]
6 53 years MM (1) Three cycles of VAD
(2) High-dose melphalan: Prednisolone and cyclosporin A for erythroderma
AITL (Lymph node) Nodular infiltration of atypical lymphocytes with large nucleoli. Positive Brain, axillary and inguinal lymph nodes 10 months Resolved [17]
Our case 53 years DLBCL (1) Six cycle of R-CHOP
(2) Three cycles of R-ACES
PTCL-NOS (Lung) Diffuse infiltration of small to medium-sized lymphocytes with multiple granulomas. Positive Supraclavicular, mediastinal, hilar, paraaortic, mesenteric lymph nodes, lungs 4 years Fatal  
  1. HL Hodgkin lymphoma, AITL angioimmunoblastic T-cell lymphoma, FL follicular lymphoma, DLBCL diffuse large B-cell lymphoma, MM multiple myeloma, PTCL-NOS peripheral T-cell lymphoma, not otherwise specified, T-LGL T-cell large granular lymphocytic leukemia, R-CHOP rituximab, cyclophosphamide, doxorubicin, and vincristine, MINE mesna, ifosfamide, mitoxantrone, and etoposide, ESHAP etoposide, cytarabine, cisplatin, and methylprednisolone, MCVAC ranimustine, cytarabine, etoposide, and cyclophosphamide, VAD vincristine, doxorubicin, and dexamethasone, CVP cyclophosphamide, prednisolone, and vincristine, AutoHASCT autologous hematopoietic stem cell transplantation, R-ACES rituximab, high-dose Ara C, carboplatin, etoposide, and steroids